For example, endometrioid adenocarcinoma, a type I endometrial cancer, exhibits rates of K-Ras and p53 mutations of 26 and 17%, respectively, whereas in serous adenocarcinoma, a type II endometrial cancer, these rates are 2 and 93%, respectively (11). Here, KRAS is linked to endometrioid adenocarcinoma.